TICKERNERD
Menu
IDXXIDXXHealthcare · Diagnostics & Research

IDXX Stock Forecast: IDEXX Laboratories, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$507
−1.70% on the day

The 13 Wall Street analysts covering IDEXX Laboratories, Inc. hold a median 12-month price target of $705 — +39.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$41.6B
Ticker Nerd rank
92 / 100
Median analyst target
$705
Analysts covering
13
Revenue$1.2B+9.7% y/y
Operating income$425.6M
Net income$338.4M
Free cash flow$320.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
−5.4%
YTD
−25.1%
1Y
−19.2%
From 52W high
−33.9%
From 52W low
+0.4%
$505
$767
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IDXX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IDEXX Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Issuance
97
Volatility
92
Value
89
Revisions
73
Growth
68
Accruals
56
Momentum
48
Size
6

Quality (99): The business earns solid, repeatable profits on what it owns.

Momentum (48): The shares have been drifting down relative to others.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IDXX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IDXX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800Jan 26Apr 26Jul 26Oct 26IDXXHigh $805Median $705Low $470

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
8 Buy4 Hold1 Sell
Low $470Median $705High $805

The green dot is the last close — the median target sits +39.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 Aug 2026BarclaysMaintainsOverweight$800 → $710
5 Aug 2026CitigroupMaintainsNeutral$650 → $670
5 Aug 2026UBSMaintainsNeutral$620 → $670
27 July 2026UBSMaintainsNeutral—
27 July 2026UBSMaintainsNeutral$640 → $620
28 Apr 2026UBSMaintainsNeutral$730 → $640
28 Apr 2026UBSMaintainsNeutral—
15 Apr 2026CitigroupInitiatesNeutral—
31 Mar 2026StifelMaintainsBuy—
9 Feb 2026Piper SandlerMaintainsNeutral—
5 Feb 2026BarclaysMaintainsOverweight—
3 Feb 2026BTIGMaintainsBuy—
3 Feb 2026UBSMaintainsNeutral—
9 Dec 2025BarclaysInitiatesOverweight—
4 Nov 2025BTIGMaintainsBuy—
4 Nov 2025JP MorganMaintainsOverweight—
4 Nov 2025Morgan StanleyMaintainsOverweight—
4 Nov 2025UBSMaintainsNeutral—
31 Oct 2025StifelUpgradeBuy—
1 Oct 2025UBSInitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IDXX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IDXX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, IDEXX Laboratories, Inc. returned −19.2% against +17.7% for the S&P 500, dividends included.

IDXX vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26IDXXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IDXX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.1%
Analysts raising
11
Analysts cutting
0
Fundamentals

IDEXX Laboratories, Inc. (IDXX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.3×

Cheaper than 21% of US stocks

Price / sales
8.9×

Cheaper than 15% of US stocks

Price / book
25.2×

Cheaper than 4% of US stocks

EV / EBITDA
26.2×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
9.7%

Higher than 51% of US stocks

Earnings growth (YoY)
15.1%

Higher than 53% of US stocks

Gross margin
64.0%

Higher than 77% of US stocks

Operating margin
35.0%

Higher than 89% of US stocks

Net margin
25.0%

Higher than 86% of US stocks

Returns & dividend
Return on equity
74.2%

Higher than 95% of US stocks

Return on assets
27.1%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IDEXX Laboratories, Inc. (IDXX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IDEXX Laboratories, Inc. has a market value of $41.6B and an enterprise value of $42.4B.

  • Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 9.7% year on year.

  • Net income over the same four quarters: $1.1B, a 25.0% net margin.

  • Diluted earnings per share, trailing twelve months: $14.22.

  • Free cash flow in the twelve months to 30 June 2026: $1.2B.

  • IDEXX Laboratories, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 78.9M.

  • Trailing P/E: 36.3×; forward P/E: 30.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • IDEXX Laboratories, Inc. employs 11,000 people — $414K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

IDXX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
IDXXIDEXX Laboratories, Inc.$41.6B
92
ILMNIllumina, Inc.$41.3B
95
IQVIQVIA Holdings, Inc.$42.8B
93
WATWaters Corp.$42.8B
53
AAgilent Technologies, Inc.$48.0B
87
MTDMettler-Toledo International, Inc.$31.3B
91
NTRANatera, Inc.$55.3B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IDEXX Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IDXX news & analysis

IDEXX Laboratories to Release 2026 Third Quarter Financial Results

Business Wire · 1 Oct 2026neutral

IDEXX Laboratories has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The company will hold an analyst conference call at 8:30 a.m. ET that day, with a live webcast, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot available via a link on the IDEXX website.

Why it matters — The announcement provides IDXX watchers with the date and access details for the company's upcoming third quarter earnings report, which will offer insight into its recent financial performance.

Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories

PRNewsWire · 30 Sept 2026positive

Chicago Pacific Founders announced the exit of its investment in CoVetAI following the company's acquisition by IDEXX Laboratories. The exit represents the first realization from the specialist animal health fund's inaugural vehicle.

Why it matters — The acquisition expands IDEXX's position in the animal health technology space and marks a completed deal that broadens its portfolio through CoVetAI.

Should You Continue to Hold IDXX Stock in Your Portfolio?

Zacks Investment Research · 23 Sept 2026neutral

Zacks Investment Research examines whether investors should continue holding IDEXX Laboratories stock, weighing its compound annual growth, expanding software adoption, and global gains against headwinds from foreign exchange effects and weaker U.S. veterinary visit volumes.

Why it matters — IDXX watchers would care because the analysis highlights both the company's continuing growth drivers and the key risks—currency effects and softening U.S. veterinary activity—that could influence its near-term performance.

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

MarketBeat · 20 Sept 2026positive

IDEXX Laboratories executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference. They also reaffirmed confidence in its long-term growth framework despite continued pressure on veterinary office visits.

Why it matters — The remarks signal that management remains confident in IDEXX's long-term strategy even amid ongoing headwinds from softer veterinary visit volumes.

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

MarketBeat · 20 Sept 2026positive

IDEXX executives presented at the Morgan Stanley Global Healthcare Conference, reiterating the company's long-term growth framework and highlighting veterinary diagnostics demand, product innovation, commercial investments, and recurring-revenue economics as key drivers, including in cancer testing.

Why it matters — An IDXX watcher would care because the company reaffirmed its growth strategy and identified specific drivers, including cancer testing, that could support its long-term trajectory.

FAQ

Frequently asked questions about IDXX stock

What is the IDXX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering IDEXX Laboratories, Inc. have a median 12-month price target of $705, with estimates ranging from $470 to $805. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IDXX stock a buy right now?

Of the 13 analysts covering IDEXX Laboratories, Inc., 8 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks IDEXX Laboratories, Inc. 92 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IDXX?

As at 6 Oct 2026, IDEXX Laboratories, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will IDXX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +39.1% from the last close, and Ticker Nerd's factor model ranks IDEXX Laboratories, Inc. 92 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IDXX stock forecast for 2030?

No analyst covering IDEXX Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IDXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $470 to $805 over the next 12 months.

How has IDXX stock performed over the past year?

IDEXX Laboratories, Inc. returned -19.2% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IDEXX Laboratories, Inc. do?

IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing.

What is the latest news on IDXX?

The most recent item we track (Business Wire, 1 Oct 2026): "IDEXX Laboratories to Release 2026 Third Quarter Financial Results". IDEXX Laboratories has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The company will hold an analyst conference call at 8:30 a.m. ET that day, with a live webcast, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot available via a link on the IDEXX website.

Company

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.

CEO Mr. Michael G. Erickson Ph.D. · 11,000 employees · United States · https://www.idexx.com